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Regulation of cancer epigenomes with a histone-binding
synthetic transcription factor
David B. Nyer1, Rene M. Daer1, Daniel Vargas1, Caroline Hom1 and Karmella A. Haynes1
Chromatin proteins have expanded the mammalian synthetic biology toolbox by enabling control of active and silenced states at
endogenous genes. Others have reported synthetic proteins that bind DNA and regulate genes by altering chromatin marks, such
as histone modifications. Previously, we reported the first synthetic transcriptional activator, the “Polycomb-based transcription
factor” (PcTF) that reads histone modifications through a protein–protein interaction between the polycomb chromodomain motif
and trimethylated lysine 27 of histone H3 (H3K27me3). Here, we describe the genome-wide behavior of the polycomb-based
transcription factor fusion protein. Transcriptome and chromatin profiling revealed several polycomb-based transcription factor-
sensitive promoter regions marked by distal H3K27me3 and proximal fusion protein binding. These results illuminate a mechanism
in which polycomb-based transcription factor interactions bridge epigenomic marks with the transcription initiation complex at
target genes. In three cancer-derived human cell lines tested here, some target genes encode developmental regulators and tumor
suppressors. Thus, the polycomb-based transcription factor represents a powerful new fusion protein-based method for cancer
research and treatment where silencing marks are translated into direct gene activation.
npj Genomic Medicine  (2017) 2:1 ; doi:10.1038/s41525-016-0002-3
INTRODUCTION
Proteins from the gene regulatory complex known as chromatin
mediate stable, epigenetic expression states that persist over
multiple cell divisions in metazoan tissues. Harnessing the potent
gene-regulating functions of chromatin proteins has become a
high priority for cancer therapy and tissue engineering. The
“histone code” model of chromatin function1 has strongly
influenced work in epigenetic engineering and drug develop-
ment.2,3 According to this model, biochemical marks are written
onto DNA-bound histone proteins and these marks are read when
effector proteins physically interact with the modified histones.
Then the effector proteins enhance or inhibit transcription
initiation. Much of our current understanding about chromatin-
mediated gene regulation comes from deconstructive methods
such as genetic mutations and RNA interference (for examples, see
refs 4–6). Constructive approaches, where synthetic systems are
built from chromatin components, are gaining recognition as an
important and powerful research method7 as well as a powerful
application for biomedical engineering.Since the references were
not in order it is has been rearranged it.
We constructed a synthetic transcription factor based on the
natural effector protein CBX8. In many human cancers, lysine 27
on histone H3 (H3K27) becomes marked by trimethylation at
abnormally high levels near tumor suppressor loci. CBX8-
containing complexes accumulate at H3K27me3 and repress gene
transcription.8 A central step in the polycomb pathway is the
specific interaction between the H3K27me3 mark and a hydro-
phobic binding pocket within the polycomb chromodomain (PCD)
motif of CBX paralogs.9,10 We used this interaction to design a
polycomb-based transcription factor (PcTF) that has VP64
(tetrameric VP16) and a visible red fluorescent tag (mCherry
RFP) fused to the C terminus of the 60 amino acid PCD. The C-
terminal VP64 domain allows PcTF to stimulate activation at
repressed H3K27me3-associated genes (Fig. 1a). In previous work,
we demonstrated H3K27me3-dependent PcTF activity at a model
locus (UASTk-luciferase). PcTF also activated endogenous silenced
loci in an osteosarcoma cell line (U-2 OS).11 Low-resolution protein
mapping experiments at four loci identified two promoter regions
that were co-occupied by PcTF and H3K27me3. Further investiga-
tion is needed to understand and accurately predict targets of the
PcTF transcription activator. Here, we report genome-wide
analyses that substantially advance our understanding of PcTF
function. PcTF-stimulated gene activation in three different cancer
cell types identified a large cohort of universally upregulated
genes with a signature H3K27me3 enrichment profile. PcTF is
enriched at transcription start sites within the nucleosome-free
region of promoters and this profile depends upon the methyl-
histone-binding PCD domain. We present a model where PcTF
bridges distal H3K27me3 with endogenous transcription factors
near the transcription start site. These findings provide significant
progress towards predicting targets of PcTF based on distributions
of epigenomic marks.
RESULTS
Common polycomb-silenced loci are activated in
PcTF-expressing cells
We measured PcTF-mediated activation of known polycomb
targets in three different cell lines, osteosarcoma (U-2 OS),
neuroblastoma (SK-N-SH), and leukemia (K562). We selected a
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panel of 14 genes for which polycomb-mediated silencing is
supported by genetic and pharmacologic disruption studies5,12–21
and protein mapping studies22–25 in human cancers and stem
cells: ATF3, CADM1, CASZ1, CDH1, CDKN2A, CLU, HK2, HOXA6,
HOXB4, IRF8, LAMB3, RUNX3, TRIM22, and WT1. We transfected U-2
OS, SK-N-SH, and K562 cells with a PcTF-expressing plasmid (Fig. 1)
via Lipofectamine LTX and allowed transfected cells to grow for
24, 48, and 72 h prior to further analysis. Flow cytometry showed
that ~24–50% were RFP-positive 24 h post-transfection, and this
number decreased roughly twofold every 24 h (Table S1). No RFP
signal was detected in K562 at 72 h. Therefore, this sample was
omitted from further experiments. We used quantitative reverse
transcription PCR (qRT-PCR) to measure mRNA from mock-
transfected (vehicle only) and plasmid-transfected cells (Fig. 1a).
Primers and dye-conjugated hydrolysis probes are described in
Table S2. We observed a decrease in PcTF transcripts over time
(Fig. S1, Table S2) and therefore adjusted fold-change ratios based
on initial PcTF transcript levels at 24 h (see Methods). In all three
cell lines, over half of the genes were activated two-fold or higher
compared to mock-transfected controls (Fig. 1b). Next, we carried
out a control experiment to determine whether the histone-
binding domain (PCD) was necessary for PcTF-mediated activa-
tion, as illustrated in Fig. 1a. To this end, we used delta-TF (ΔTF), a
fusion protein that lacks the PCD histone-binding motif. Failure of
ΔTF to upregulate genes in many cases demonstrated that the
PCD was required to regulate a subset of target genes (Fig. 1b, Fig.
S1). IRF8, CADM1, and RUNX3 became activated in the presence of
PcTF but not the PCD-deleted control in all three cell types. CASZ1,
HOXB4, CLU, CDKN2A, WT1, and HOXA6 were specifically upregu-
lated in the presence of PcTF in two of the three cell types. Other
genes that became activated in the presence of TF suggest a
general stress-response to transfection, as observed in other
work.26
In our previous work, we used an intercalating dye (SYBR green)
for qRT-PCR and observed that CDKN2A was strongly upregulated
by PcTF compared to ΔTF in U-2 OS cells.11 Here, our hydrolysis
probe assay, which is more specific than the intercalating dye,
shows modest upregulation (FC log2 = 0.68) of CDKN2A at the 24 h
time point in U-2 OS and stronger upregulation in K562. CDKN2A is
not upregulated in SK-N-SH. By including several more known
polycomb targets, we have identified other genes that are
specifically upregulated by PcTF in all three cell types: IRF8,
CADM1, and RUNX3.
PcTF stimulates expression of a large subset of H3K27me3-marked
genes in U-2 OS, SK-N-SH, and K562 cells
Whole-transcriptome analysis revealed a larger subset of PcTF-
sensitive genes. We performed next-generation deep sequencing
of total RNA (RNA-seq) from mock transfected (control) and PcTF-
expressing cells (+PcTF) up to 96 h post-transfection. An increase
in alignments to CBX8, which matches the first ~200 bp of the
PcTF open reading frame, indicated expression of the PcTF
transgene (Fig. 2a). Whole-transcriptome analysis of U-2 OS
corroborated the qRT-PCR results for the PcTF-sensitive genes
CASZ1, HOXB4, IRF8, and WT1. Comparison of fragments per
kilobase of gene model per million mapped reads (FPKM) for
control samples vs. fold change after PcTF expression showed that
13.4% of 23,245 annotated Refseq genes became up-regulated
twofold or higher (Fig. 2a). CASZ1 and 193 other genes showed
upregulation in all three cell types (Fig. 2b).
Fig. 1 PcTF expression stimulates upregulation of known targets of Polycomb in transiently transfected cells. a Map of the PcTF-expressing
plasmid (top). The natural PRC1 complex mediates gene silencing (middle). PcTF expression leads to accumulation of PcTF at H3K27me3 and
gene activation (bottom).11 b Transiently-transfected U-2 OS, SK-N-SH, and K562 cells were visualized via the mCherry red fluorescent protein
(RFP) tag. qRT-PCR was used to determine mRNA levels of fusion protein transcripts (PcTF or ΔTF) and a panel of 14 target genes at 24, 48, and
72 h post-transfection. RFP signal was not detected in K562 after 48 h, therefore later time points were omitted for K562 in this assay and other
experiments. The heat map shows scaled, average log2 fold change ratios for GAPDH-normalized expression in plasmid-transfected cells
compared to cells mock-transfected with the vehicle (Lipofectamine LTX) only. Standard deviations are shown in Fig. S1
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We also observed down-regulation (fold-change≤2) at 9.2% of
the genes in U-2 OS. Fifty of these genes also became
downregulated in SK-N-SH and K562. Repression is inconsistent
with the transcriptional activation function of VP64. Based on the
RNA-seq results alone, we speculated that the upregulated genes
might be direct targets of PcTF (as illustrated in Fig. 1a) and that in
some cases PcTF might up-regulate endogenous transcription
regulators such as gene silencers that produce secondary effects.
Seventy-six of the genes that are upregulated twofold or higher
encode microRNAs, which silence gene expression by blocking
translation of messenger RNA. MicroRNAs often have several
targets, such as MIR3658, which has 126 target genes (miRTar-
Base)27 and is upregulated in U-2 OS and SK-N-SH. MIR1248 has
154 target genes and is upregulated in SK-N-SH and K562. PcTF
might also disrupt expression at the repressed genes by placing
VP64 in a suboptimal position relative to the promoter.28,29
To investigate further, we used data from chromatin immuno-
precipitation followed by deep sequencing (ChIP-seq) experi-
ments to look for an epigenetic signature of PcTF-sensitive genes.
We determined the enrichment of H3K27me3 at the 14 Polycomb
targets (Fig. 1b) and near transcription start sites (TSS’s) of over
23,000 annotated human genes. In U-2 OS, ChIP was performed as
previously described using an antibody against H3K27me3.11 DNA
was purified from the immunoprecipitated chromatin, analyzed by
next generation deep sequencing, and reads were aligned to the
hg19 human genome consensus (Feb. 2009 GRCh37). Regions of
enrichment compared to non-immunoprecipitated bulk chroma-
tin (input) were calculated using the Hotspot algorithm.30 We used
shared and public data to determine H3K27me3 enrichment in SK-
N-SH and K562 cells. CASZ1, IRF8, and CADM1 are marked by
H3K27me3 (Fig. S2) and become upregulated upon PcTF
expression in all three cell types. CLU and HOXA6 are enriched
Fig. 2 Genome-wide analysis of gene transcription and H3K27me3 at promoter regions in PcTF-expressing cells. a The scatter plot compares
RNA-seq signals (FPKM log10) of 23,245 genes from cells that were mock transfected (Control) vs. log2 fold change of PcTF-expressing cells 96
h post-transfection for U-2 OS and SK-N-SH and 48 h for K562. Housekeeping genes GAPDH, ACTB, and CHMP2A are negative controls. b The
Venn diagram shows unique and common sets of genes that became up-regulated at least twofold in the three cell types. Overall, 194
commonly up-regulated genes and 50 commonly downregulated genes are highlighted in the scatter plots. The PcTF-homologous CBX8 gene
was used as a proxy for PcTF expression levels. c TSS plots (orange, top) show total H3K27me3 ChIP enrichment values mapped at 200 bp
intervals with a step value of 50 bp. In the lower plots, values are stratified by the basal gene expression level in untreated cells (Control FPKM
log10). Stratified TSS-plot data were normalized by the gene distribution for each category
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for H3K27me3 in two cell types, and only become up-regulated
when H3K27me3 is present (Fig. S2). These results are consistent
with a mechanism where PcTF accumulates at H3K27me3 sites
and induces gene transcription.
Overall, H3K27me3 enrichment was depleted near transcription
start sites at silenced and active genes, indicated by a sharp valley
at position zero in stratified TSS-plots (Fig. 2c). This profile has
been observed in other reports; similar plots show a valley in the
TSS profile at the nucleosome-free region (NFR) of promoters in
mammalian cells.31,32 Genes with lower basal expression levels,
prior to PcTF expression, show the highest levels of H3K27me3
enrichment, which is consistent with the role of H3K27me3 in
gene silencing. Genes that became up-regulated in response to
PcTF expression showed the highest H3K27me3 levels compared
to non-responsive and down-regulated genes in K562 cells (Fig.
S3). In SK-N-SH and U-2 OS however, up-regulated genes showed
the same or lower H3K27me3 levels as non-responsive genes.
Therefore, PcTF-sensitivity may not be determined by the mere
presence of H3K27 methylation within 5 kb of the transcription
start site. Instead, positioning of H3K27me3 relative to the TSS
might distinguish PcTF-sensitive genes.
We hypothesized that a specific H3K27me3 distribution pattern
around the TSS determines which genes are activated by PcTF. For
a subset of 194 commonly upregulated genes H3K27me3 is
depleted at the TSS, which is surrounded by signal peaks at
intervals of roughly 1 kb (Fig. S3). The highest peaks for K562 were
observed immediately downstream of the TSS and 3 kb upstream.
These data suggest that PcTF-mediated activation of silenced
genes may rely on H3K27me3 enrichment at positions distal to the
TSS.
ChIP analyses in stable transgenic U-2 OS cells shows PCD-
dependent enrichment of PcTF near transcription start sites
In order to further investigate the mechanism of PcTF-mediated
gene regulation, we used crosslinked chromatin
immunoprecipitation (X-ChIP, referred to as “ChIP” here) to
measure the accumulation of PcTF and H3K27me3 at a single
locus and throughout the genome. For these studies, we used an
isogenic PcTF-expressing U-2 OS cell line. The cell line “U2OS-
PcTF” carries a chromosomally-integrated, TetR-repressed gene
that expresses myc-tagged PcTF when the cells are treated with
doxycycline (dox) (Fig. 3a), as described previously.11 Five of the
eight genes that we identified as specifically PcTF-sensitive
(Fig. 1b) showed a dose-dependent response to PcTF in U2OS-
PcTF cells. Flow cytometry of cells treated with none or 0.016–1
μg/ml dox for 72 h showed dose-dependent median RFP intensity
(Fig. 3b). Frequencies of RFP-positive cells were the same across
samples (Fig. S4), indicating that dox dosage regulated the
amount of PcTF per cell. PcTF transcript levels also increased with
dox dose, as shown by qRT-PCR (Fig. 3c). Expression of HOXB4,
CADM1, RUNX3, CASZ1, and CDKN2A increased with higher levels
of PcTF (Pearson R2 = 0.67–0.98). IRF8, CLU, and WT1 expression
decreased with increasing PcTF, suggesting that perhaps regula-
tion of these three genes is complex and may involve endogenous
factors that oppose activation. Overall, our dose-response experi-
ment validated U2OS-PcTF as a robust system to further
investigate PcTF-mediated gene regulation.
In order to investigate the kinetics of PcTF engagement with a
target gene, we measured accumulation of myc-tagged PcTF,
H3K27me3, RNA PolII, and H3K4me3 (an activation-associated
mark)33 at a PcTF-sensitive locus in U2OS-PcTF cells that were
formaldehyde-fixed at different time points after dox treatment. A
time course flow cytometry analysis of RFP in U2OS-PcTF cells
confirmed PcTF accumulation over time from 2 to 10 h (Fig. S5).
For ChIP analysis, we used CASZ1 as a model locus. This gene was
consistently upregulated by PcTF in the three cells types tested
here, responded to PcTF in a dose-dependent manner in U2OS-
PcTF, and the locus is free of other overlapping or nearby genes
that might complicate analysis. We analyzed five sites by
quantitative PCR (qPCR) of DNA from IP-enriched chromatin.
These sites were located at the TSS and along 10 kb of the
Fig. 3 Polycomb-repressed genes become activated by PcTF in a dose-dependent manner. a The illustration shows doxycycline (dox) induced
PcTF expression in U2OS-PcTF cells, leading to accumulation of PcTF at H3K27me3-positive promoters and gene activation.11 b Flow
cytometry analysis of dox-treated cells. Grey bars show average RFP signal (n= 3, Error= standard deviation). RFP signal histograms and RFP-
positive cell frequency are shown in Fig. S4. c qRT-PCR analysis of PcTF and eight genes that showed PcTF-specific activation in transiently
transfected U-2 OS cells. The heat map shows average (n= 3) log2 fold change ratios for GAPDH-normalized expression in dox-treated cells
compared to one of the untreated replicates. R2= Pearson correlation coefficient of average log2 fold change values for target genes vs. PcTF
Regulation of cancer epigenomes
DB Nyer et al
4
npj Genomic Medicine (2017)  1 Published in partnership with the Center of Excellence in Genomic Medicine Research
upstream region (Fig. 4a). A GAPDH TSS-proximal site was used as
a negative control for PcTF and H3K27me3, and a positive control
for H3K4me3 and PolII.
Prior to dox treatment (0 h), the CASZ1 locus showed H3K27me3
enrichment ~ 2 kb upstream, and at lower levels at other sites,
including the TSS (Fig. 4a, Fig. S6). PolII and the active H3K4me3
mark were also enriched at the TSS, suggesting that CASZ1 is near
a bivalent, poised promoter.24 After dox treatment, PcTF enrich-
ment was observed near the TSS of CASZ1 at 10, 24, and 48 h post
induction. Over time, H3K27me3 levels fluctuated and then
decreased at 48 h. In summary, we show that the H3K27me3
mark is present as PcTF accumulates at CASZ1. The results suggest
that PcTF-mediated gene activation is followed by a loss of the
H3K27me3 silencing mark.
We observed stronger PcTF enrichment at the TSS than at the
strongest H3K27me3 signal 2 kb upstream, suggesting that PcTF
binding might be controlled by interactions between VP64 and
endogenous transcription factors rather than by the PCD domain. To
investigate the function of the PCD we used a dox-inducible stable
cell line, U2OS-PCD, which expresses a truncated version of PcTF
that contained the PCD, mCherry, and the myc tag, but lacks the
VP64 activation domain.11 The binding profile of PCD showed
enrichment across the 10 kb region upstream of CASZ1, which
overlapped with H3K27me3 10 h. after induction (Fig. 2b). This result
suggests that the PCD motif is functional within the fusion protein.
We therefore surmised that there is synergy between the function of
the PCD domain, required for the activation of CASZ1 and other
genes, and the VP64 domain, required for enrichment near the TSS.
To further investigate the mechanism of PcTF-mediated gene
regulation, we used ChIP-seq to compare the distribution of PcTF
and H3K27me3 throughout the genome and at TSS regions. A
parental U-2 OS cell line (Flp-in T-Rex, Invitrogen) was used to
observe unaltered H3K27me3 patterns in the absence of PcTF.
ChIP-seq analysis of an isogenic, dox-inducible U2OS-ΔTF cell
line11 showed little overlap of ΔTF with PcTF and H3K27me3 (Fig.
S7), which indicated that PcTF and H3K27me3 distributions were
not due to random crosslinking. We analyzed the distributions of
PcTF and H3K27me3 ChIP at different genomic features and
observed the greatest enrichment over background for intergenic
regions (Fig. S7). PcTF, but not H3K27me3, showed signal
enrichment at promoters. These results indicate that PcTF and
H3K27me3 co-occupy non-coding regions, and that PcTF is
frequently enriched at promoter sites.
We inspected promoter regions more closely by identifying
PcTF and H3K27me3-enriched regions surrounding TSS’s. We
identified 5535 total regions that were marked with PcTF or
H3K27me3 or both. A TSS plot showed a peak of PcTF enrichment
at the TSS over a 2 kb interval (Fig. 4b). Randomly crosslinked ΔTF
did not show the same enrichment profile, therefore mCherry-
tagged VP64 alone does not account for the enrichment pattern
of PcTF. In contrast to PcTF, H3K27me3 was depleted at the TSS.
The subset of 316 regions in which we detected both PcTF and
H3K27me3 showed a similar but shorter PcTF enrichment peak
(Fig. S7). H3K27me3 signal was depleted near the TSS, with
dispersed peaks of H3K27me3 further from the TSS. The profiling
data suggest that at co-occupied regions, PcTF enrichment
appears at and adjacent to the TSS, while H3K27me3 is farther
away either upstream or downstream. Overall, these results
suggest that PcTF accumulates near the TSS, and that this
accumulation depends upon interaction with distal H3K27me3
through the N-terminal PCD peptide.
Up-regulated genes are marked by H3K27me3 upstream and PcTF
near the TSS in U2OS-PcTF cells
Up-regulation of PcTF-sensitive genes corresponds with H3K27me3
enrichment at roughly 1–2 kb upstream of the transcription start
site in regions where we also detected PcTF enrichment near the
TSS. To identify up-regulated genes, we compared RNA-seq FPKM
values of 23,245 genes for doxycycline-induced U2OS-PcTF cells
Fig. 4 ChIP-PCR and ChIP-seq analysis of PcTF and H3K27me3 distribution in U2OS-PcTF cells. a The map shows the location of primer pairs
and amplicons (Table S3) used to analyze DNA from IP-enriched chromatin. Heat maps show averages of triplicate qPCR reactions from
duplicate (PolII, H3K4me3) or triplicate (Myc, H3K27me3) immunoprecipitations. Standard deviations are shown in the bar graphs in Fig. S6. b
The Venn diagram compares genes that have PcTF- and H3K27me3-marked TSS regions (−5 to +5 kb). TSS-centered plots show the total ChIP
hotspot signal value within a sliding window of 200 bp (step size= 50 bp)
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and U2OS-ΔTF cells. Agreement between U2OS-PcTF RNA-seq
results was confirmed by DEseq2 comparison of reads alignments
per gene (Fig. 5a). Six of the specifically PcTF-activated genes
identified previously (Fig. 1b) showed upregulation in the RNA-seq
results: IRF8, CASZ1, RUNX3, HOXB4, and WT1. We observed a
significant (p < 0.05) increase in expression for two of these
upregulated genes, IRF8 and CADM1 (Fig. 5a). For transcript levels
that changed at least twofold in either direction, the predominant
response was an increase in expression of genes that had a low
initial expression state in control cells. FPKM values of silenced
genes are typically lower than 1.34 The frequency of upregulated
genes within the non-expressing FPKM range of 10−4–100 was
23%, whereas only 3% of active genes were upregulated (Fig. 5a).
Stratified TSS plots showed that PcTF was frequently enriched
immediately downstream of the TSS at up-regulated genes
(Fig. 5b). H3K27me3 was depleted near the TSS and showed
peaks of enrichment 1 kb, 2 kb, and 4 kb upstream. Median
distances of the nearest H3K27me3 signal were −2545.5 bp for 2-
to 8-fold up-regulated genes and −1365 bp for genes that were
up-regulated eightfold or higher (Fig. 5c). For genes that showed
no change or were down-regulated, median distances ranged
from −588.5 to 93.5 bp. Positioning of H3K27me3 very close to the
TSS at non-responsive and down-regulated genes might interfere
with VP64-driven gene activation, or cause VP64 to recruit
transcription factors to a site that is not optimal for proper
transcription. These data indicate that a distal H3K27me3 mark
positions PcTF at an optimal position to allow the VP64 activation
domain to stimulate gene transcription at target promoters.
PcTF-sensitive loci are located near H3K27me3-marked promoters
and repressed regions
Non-coding, intergenic regions play an important role in protein-
mediated gene regulation. Many of these regions contain
elements that show conservation of epigenetic marks across
human cell types.35 In order to deepen our understanding of PcTF-
sensitive sites, we investigated local chromatin features at genes
that were upregulated, down-regulated or showed no change in
response to PcTF in U-2 OS, SK-N-SH, and K562 cells. Investigation
of the chromosomal positions of PcTF-sensitive genes, H3K27me3,
and 15 classes of human chromatin states revealed that histone
Fig. 5 Analysis of genome-wide regulation in U2OS-PcTF cell and H3K27me3 localization. a The scatter plot compares RNA-seq signals (FPKM
log10) of dox-induced ΔTF cells vs. the log2 fold change in expression compared to U2OS-PcTF cells (same color scheme as in Fig. 2a). Known
Polycomb-regulated genes and control genes from Figs. 1 and 2 are highlighted for comparison with previous experiments. The volcano plot
shows statistical significance vs. fold change for triplicate U2OS-PcTF samples. b TSS-centered plots show the total ChIP hotspot signal value
(window= 200 bp, step size= 50 bp) stratified by log2 fold-change expression. c H3K27me3 ChIP signal distances from the TSS were
compared for genes of lengths ≥2 kb in the subset of 316 genes where the 10 kb region is co-occupied by PcTF and H3K27me3. Genes were
grouped by fold-change expression (as in b). Box plots show median values (solid vertical line), 25th (left box) and 75th (right box) percentiles,
and minimum (left whisker) and maximum values (right whisker). TSS maps drawn to scale show the midpoints of ChIP signals for H3K27me3
(orange circle) and PcTF (red square) relative to the TSS. Genes are sorted from highest to lowest log2 fold-change value
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methylation near poised promoters and repressed regions
corresponds with PcTF-mediated gene activation. Regions of
interest were identified using the 15 classes of human chromatin
states from the ENCODE project for nine different human cell
types,35 including K562. Coordinates for elements of all 15 classes
were extracted in tabular format from hg19 annotations from the
public K562 cell data (UCSC Genome Browser). We identified the
closest element upstream or downstream of 23,245 TSS’s and
calculated median distances between the midpoint of each
element and the TSS (Fig. 5a). Genes with FPKM values of zero
in both control and treated cells were excluded from the
calculations. Compared to non-responsive genes (log2 fold-
change <2 in either direction), both up- and down-regulated
genes were located near class 3 poised promoters, which are
characterized by the presence of H3K27me3 and H3Kme4 and are
thought to support gene state plasticity.36 Up- and down-
regulated genes also showed greater proximity to class 12
repressed regions, which are typically enriched for Polycomb-
associated marks such as H3K27me3. None of the chromatin
classes we investigated showed a significant bias in TSS proximity
specifically for the up-regulated genes. Our investigation of local
chromatin features implicates poised promoters and Polycomb-
repressed regions as factors for PcTF-sensitivity.
DISCUSSION
The work presented here provides new insights into the
mechanism of PcTF, a synthetic chromatin-based transcription
factor. PcTF couples recognition of a silencing-associated mark
with gene activation. PcTF enrichment near TSS sites is similar to
the patterns that have been observed for subunits of the
transcription initiation complex,31,37 suggesting a strong interac-
tion with endogenous transcription factors. The C-terminal
domain of PcTF includes VP64, which is composed of four copies
of a core acidic transcription activation domain (TAD) from VP16.38
The TAD is derived from the H1 region of VP16, which has been
shown to bind with high affinity (high nanomolar range) to the
mediator complex subunit MED25.39 The VP16 TAD also interacts
with MED17, several members of the transcription factor II (TFII)
family, and the TATA promoter motif-binding protein TBP
(reviewed in refs 40,41). In contrast, the C-terminal PCD has
relatively low affinity (high micromolar range) for H3K27me3.42
PCD-H3K27me3 binding may be weak in vivo, but it is still
necessary for PcTF function11 and for TSS-proximal enrichment
(Fig. 3c). Enrichment of PcTF in regions that are near to but do not
overlap with H3K27me3 was observed in our previous ChIP-PCR
studies.11 This offset of PcTF ChIP signals from H3K27me3 sites
suggests that PcTF engages with H3K27me3 and then becomes
trapped near the TSS through interactions with the transcription
initiation proteins in crosslinked chromatin. The data provide
strong evidence for a mechanism where PcTF bridges distal
histone methylation marks with PolII-associated transcription
factors at the nucleosome-free TSS (Fig. 6).
RNA-seq results for genes that do not appear to be direct
targets of PcTF-mediated activation provide additional insights
into gene regulation (Fig. 7). Many of the genes we analyzed in the
Fig. 6 Distances of nearest chromatin states to TSS’s. Genes are stratified by fold-change in expression level after PcTF expression in
transiently transfected cells. Numbers of regions nearest the TSS of genes in each category are shown in tables next to each chart. The
coordinates of poised promoters, repressed regions, and 11 other states (not shown) were determined using chromatin state classes from the
ENCODE project (UCSC Browser HMM track for K562 cells).35 U2 = U-2 OS, SK = SK-N-SH, K5 = K562
Fig. 7 Model for PcTF-mediated gene activation.57, 58
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RNA-seq experiments do not change more than twofolds or
become down-regulated after PcTF expression. In these cases,
suboptimal positioning of the VP64 domain of PcTF relative to the
promoter might neutralize its activity or lead to reduced
expression below basal levels.28,29 We observed several genes
that became up- or down-regulated, but lacked a PcTF signal
within 10 kb of the TSS. Regulation of these genes could be
mediated by transcription regulators that are direct targets of
PcTF. For example up-regulated, PcTF-marked genes such as
CASZ1 may encode broadly-acting transcriptional regulators that
control multiple targets.43,44
Our work has significant implications for medicine. Currently,
epigenetic engineering relies largely on small-molecule inhibitors
that are intended to erase cancer-associated epigenetic silencing
and indirectly activate therapeutic genes. These drugs have major
shortcomings such as incomplete erasure of cancer-associated
methyl-histone marks and DNA damage. Here, we used a
synthetic chromatin protein, PcTF, to convert the methyl-histone
signal into direct activation of therapeutic genes instead of
inhibitors to erase cancer-associated marks. Genes that were
consistently upregulated by PcTF in all three cell lines we tested
have therapeutic potential. Work by others has shown that
overexpression of the CASZ1 transcription regulator inhibits
proliferation of neuroblastoma (SH-SY5Y).45 Ectopic expression of
IRF8 in renal cell carcinoma has been shown to decrease colony
formation and migration.46 Overexpression of CADM1 reduced
proliferation in cervical cancer cell lines C33A, HeLa, SiHa, and
CaSki.47 It will eventually be important to directly compare the
efficacy of PcTF to RNAi knockdown or chemical inhibition (e.g.
UNC3866) of Polycomb proteins.12,48 This comparison will
determine whether PcTF-mediated stimulation of the transcription
activation complex at silenced genes is truly advantageous over
the simpler delivery of small molecules that inhibit polycomb and
generate indirect activation. Furthermore, work to determine the
specificity of PcTF in cancer vs. healthy cells and to enhance
efficient synthetic protein delivery will bring this promising new
fusion protein-based technology closer to translation.
METHODS
DNA constructs
The doxycycline-inducible PcTF-expressing plasmid has been described.11
The plasmid is constitutively expressed in the absence of a TetR protein (in
cell lines U-2 OS, SK-N-SH, and K562). The full annotated sequences of PcTF
(hPCD-TF, KAH126) and ΔTF (TF, KAH132) are available online at Benchling
—Hayneslab: Synthetic Chromatin Actuators (https://benchling.com/
hayneslab/f/S0I0WLoRFK-synthetic-chromatin-actuators/).
Cell culture and transfection
Complete growth media contained 10% tetracycline-free fetal bovine
serum and 1% penicillin and streptomycin (pen/strep). U-2 OS (ATCC HTB-
96), U2OS-PcTF, U2OS-PCD, and U2OS-ΔTF cells were cultured in McCoy’s
5A. K562 (CCL-243), and SK-N-SH (ATCC HTB-11) cells were cultured in
IMDM or EMEM, respectively. Cells were grown at 37 °C in a humidified CO2
incubator. U2OS-stable cell lines were generated by previously published
work.11 PcTF-expressing U-2 OS, K562, and SK-N-SH cells were generated
by transfecting 5×105 cells in 6-well plates with DNA/Lipofectamine
complexes: 2 μg of plasmid DNA, 7.5 μl of Lipofectamine LTX (Invitrogen),
2.5 PLUS reagent, 570 µl OptiMEM. Transfected cells were grown in pen/
strep-free growth medium for 18 h. The transfection medium was replaced
with fresh, pen/strep-supplemented medium and cells were grown for up
to 48 h (K562) or up to 96 h (U-2 OS and SK-N-SH).
Quantitative reverse transcription PCR (qRT-PCR)
Total messenger RNA was extracted from ~ 90% confluent cells (~1–2×106).
Adherent cells (U-2 OS and SK-N-SH) were lysed directly in culture plates with
500 μl TRIzol. Suspended cells (K562) were collected into tubes, pelleted by
centrifugation at 1000×g for 3min at room temperature, separated from the
supernatant, and lysed in 500 μl TRIzol. TRIzol cell lysates were extracted with
100 μl chloroform and centrifuged at 12,000×g for 15min at 4 °C. RNA was
column-purified from the aqueous phase (Qiagen RNeasy Mini kit 74104).
SuperScript III (Invitrogen) was used to generate cDNA from 2 μg of RNA.
Real-time quantitative PCR reactions (15 μl each) contained 1× LightCycler
480 Probes Master Mix (Roche), 2.25 pmol of primers (see Supplemental
Table 1 for sequences), and 2 µl of a 1:10 cDNA dilution (1:1000 dilution for
GAPDH and mCh). The real time PCR program was run as follows: Pre-
incubation, ramp at 4.4 °C s−1–95 °C, hold 10min; amplification, 45 cycles
(ramp at 4.4 °C s−1–95 °C, hold 10 s, ramp at 2.2 °C s−1–60 °C, hold 30 s, single
acquisition); cooling, ramp at 2.2 °C s−1–40 °C, hold 30 s. Crossing point (Cp)
values, the first peak of the second derivative of fluorescence over cycle
number, were calculated by the Roche LightCycler 480 software. Expression
level was calculated as delta Cp, 2^[Cp GAPDH–Cp experimental gene]. Fold change
(log2) was determined as delta Cp transfected cells/delta Cp mock. Plasmid
expression scaling for the values shown in Fig. 1b was performed using
normalization quotients, calculated as average fold change (log2) for mCherry
(plasmid expression) for the 24-, 48-, and 72 h time points divided by the 24 h
value. Values for target genes within each time point were multiplied by the
appropriate quotient.
RNA-seq
RNA-seq was performed using one sample per experimental condition for
transiently transfected cells and three replicates for the U2OS-PcTF and
U2OS-ΔTF cell lines. Total RNA was prepared as described for qRT-PCR.
Overall, 50 ng of total RNA was used to prepare cDNA via single primer
isothermal amplification using the Ovation RNA-Seq System (Nugen 7102-
A01) and automated on the Apollo 324 liquid handler (Wafergen). cDNA
was sheared to ~300 bp fragments using the Covaris M220 ultrasonicator.
Libraries were generated using Kapa Biosystem’s library preparation kit
(KK8201). In separate reactions, fragments from each replicate sample were
end-repaired, A-tailed, and ligated to index and adapter fragments (Bioo,
520999). The adapter-ligated molecules were cleaned using AMPure beads
(Agencourt Bioscience/Beckman Coulter, A63883), and amplified with
Kapa’s HIFI enzyme. The library was analyzed on an Agilent Bioanalyzer,
and quantified by qPCR (KAPA Library Quantification Kit, KK4835) before
multiplex pooling and sequencing on a Hiseq 2000 platform (Illumina) at
the ASU CLAS Genomics Core facility.
Bioinformatics analysis
ChIP-seq alignments were carried out using the Bowtie2 algorithm49 with
the hg19 reference genome (Feb. 2009 GRCh37). Enrichments normalized to
input were calculated using the Hotspot algorithm (distribution version 4).31
ChIP-seq data for SK-N-SH was provided by B. Bernstein and K562 data was
retrieved from the UCSC Genome Browser website.50 Galaxy (http://www.
usegalaxy.org)51 was used to identify overlaps with a minimum of 1 bp
between gene intervals and ChIP-seq enrichment intervals. Raw sequence
data (fastq) was analyzed with FastQC52 and processed to remove low-
quality reads and adapters using TrimmomaticSE.53 RNA-seq alignments
were carried out with de-multiplexed 50-bp single-end reads and the hg19
transcriptome. Within the public Galaxy online platform, splice junctions
were mapped using Tophat (Galaxy version 2.1.0) and Bowtie 2 and
transcript abundance and differential expression were calculated using
Cuffdiff54 and the Homo sapiens UCSC hg19 gene transfer format (gtf) file
from Illumina iGenomes. Out-dated genes were identified by cross-
referencing gene symbols with the NCBI database and removed from the
Cuffdiff output in Galaxy, resulting in 23,245 genes. Gene comparisons and
Venn diagrams were generated with Venny 2.1 (http://bioinfogp.cnb.csic.es/
tools/venny/)55 and Biovenn (http://www.cmbi.ru.nl/cdd/biovenn/).56 Micro-
soft Excel was used to calculate distances between features (TSS’s, ChIP
signals, and enhancers) and to generate graphs and charts.
Chromatin immunoprecipitation
Adherent U-2 OS cells were directly crosslinked in culture plates in 20ml of
1% formaldehyde (Thermo Fisher Scientific)/1× PBS (Dulbecco’s) with gentle
shaking for 10min at room temperature. Cross-linking was stopped by
adding 125mM glycine, followed by 5min gentle shaking. Quenched
formaldehyde was aspirated and cells were washed twice for 5min with
gentle shaking at room temperature with 10ml cold 1× PBS supplemented
with Pierce Protease Inhibitors (Thermo Fisher Scientific). Cells were
collected by scraping and spun at 200xg for 5min. Cell pellets were washed
twice with 10ml cold 1× PBS with Pierce Protease Inhibitors. Overall, 70 μl of
cross-linked cells were resuspended in 112.5 μl of cell lysis buffer (10mM Tris
pH 8 (ThermoFisher), 10mM NaCl, 0.2% IGEPAL (Sigma)) plus Protease
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Inhibitors and incubated on ice 10min. Lysed cells were spun for 5min at
400xg. Nuclei were resuspended and lysed in 1ml of nuclei lysis buffer (1%
sodium dodecyl sulfate (SDS) (Sigma), 10mM ethylenediaminetetracacetic
acid (EDTA) (Fisher Scientific), 50mM Tris–HCl pH 8.1 (Sigma)) plus Protease
Inhibitors and incubated on ice for 10min. Lysed nuclei were diluted with
0.5ml of ChIP dilution buffer (1% Triton X-100 (Santa Cruz Biotech), 2mM
EDTA, 150mM NaCl (Sigma), 20mM Tris–HCl, pH 8) and split into five 300 μl-
aliquots. Samples were sheared with the Qsonica Q700A Sonicator with a
5.5″ Cup Horn. Sonicated chromatin samples were spun at 16,300xg for 10
min at 4 °C to remove impurities and frozen at −80 °C. To determine
shearing efficiency, DNA from 100 μl of each sample was purified by
incubation at 65 °C in 100mM NaCl overnight, at 37 °C with 10 μg RNase A
(Sigma) for 30min, and at 62 °C with 10 μg Proteinase K (Qiagen) for 2 h.
DNA fragment sizes of ~500 bp were confirmed via electrophoresis on a 1%
agarose gel.
Overall, 30 μg of each chromatin sample per immunoprecipitation was
diluted to a final volume of 1ml in ChIP dilution buffer. Magna ChIP Protein
A + G Magnetic Beads (Millipore) were washed three times with PBS buffer
+ BSA (5 mg/ml) (Sigma). Chromatin samples were pre-cleared with 20 µl of
washed beads and nutation for 3 h at 4 °C. Twenty percent of each pre-
cleared sample was removed and set aside for input controls. Each
chromatin sample was incubated at 4 °C for 12 h with nutation with each
of the following antibodies: Anti-RNA PolII EMD Millipore 05-623, anti-
H3K27me3 EMD Millipore 07-449, anti-H3K4me3 Abcam ab8580, anti-Myc
(9B11) Mouse IgG Cell Signaling Tech 2276S, normal Mouse IgG Sigma
18765 (mock), and normal Rabbit IgG Cell Signaling Tech 2729S (mock).
Magna ChIP Protein A + G beads were blocked by three washes in PBS
buffer + BSA (5 mg/ml). Next, 20 μl of blocked beads were added to each
antibody-chromatin and incubated for 3 h at 4 °C with nutation.
Chromatin-antibody-bead complexes were washed twice for 10min in
RIPA buffer (50mM HEPES pH 7.6 (Thermo Fisher Scientific), 1 mM EDTA,
0.7% sodium-deoxycholate (Sigma), 1% IGEPAL CA-630 (Sigma), 0.5 M LICl
(Sigma)), twice for 10min in a mild deteregent solution (20mM Tris pH 8, 2
mM EDTA, 50mM NaCl, 1% Triton X100, 0.1% SDS), and twice for 10min in
tris-EDTA pH 7.6 (Sigma). Elution of specifically bound chromatin was
carried out in 100 μl of elution buffer (1% SDS, 0.1 M sodium bicarbonate
(Sigma), 0.1 M NaCl). Inputs were thawed and brought to 100 µl with
elution buffer. Samples were incubated for 30min with nutation at room
temperature. DNA was purified as described above, cleaned with a
QIAquick PCR Purification Kit (Qiagen), and eluted in 50 µl nuclease-free
water.
Deep sequencing of DNA from immunoprecipitated chromatin
(ChIP-seq)
Chromatin immunoprecipitation was performed on U-2 OS Flp-In T-Rex
cells, which carry a chromosomal insert of a TetR-repressible PcTF gene as
previously described.11 A ChIP-Seq DNA Sample Prep Kit (Illumina IP-102-
1001) was used to prepare deep sequencing libraries from DNA that was
purified from immunoprecipitated (IP) and non-IP (input) chromatin. End-
repair was carried out at 20 °C for 30min in the following 50 µl reaction: 30
µl ChIP DNA, 1× T4 DNA ligase buffer, 0.4 mM dNTP, 1 µl T4 DNA
polymerase, 1 µl Klenow DNA polymerase, 1 µl T4 polynucleotide kinase.
End-repair products were concentrated into a final volume of 34 µl Qiagen
elution buffer (QIAquick PCR Purification kit 28104). 3′-end adenine base
extension was carried out at 37 °C for 30min in the following 50 µl
reaction: 34 µl end-repair reaction product, 1× Klenow buffer, 0.2 mM
dATP, 1 µl Klenow exonuclease. Base extension products were concen-
trated into a final volume of 10 µl H2O (Zymo Clean and Concentrator
D4003). Adapter ligation was carried out at room temperature for 15min in
the following 30 µl reaction: 10 µl 3′-base extension reaction product, 1×
ligase buffer, 1 µl adapter oligo mix, 4 µl DNA ligase. Ligation products
were concentrated into a final volume of 10 µl H2O (Zymo Clean and
Concentrator D4003). A total of 150–200 bp fragments from each ligation
reaction were resolved and purified via gel electrophoresis and extraction
(Zymoclean Gel DNA recovery kit D4001). DNA was back-eluted from the
column twice with 10 µl H2O and brought to a final volume of 36 µl.
Adapter-modified 150–200 bp fragments were enriched by the PCR in the
following 50 µl reaction: 36 µl gel-purified DNA, 1× Phusion buffer, 0.3 mM
dNTP, 1 µl PCR primer 1.1, 1 µl PCR primer 2.1, 0.5 µl Phusion polymerase.
The cycling program was 98 °C/30 s, 18 cycles (98 °C/10 s, 65 °C/30 s, 72 °C/
30 s), 72 °C/5 min, 4 °C/∞. PCR products were concentrated into a final
volume of 15 µl H2O (Zymo Clean and Concentrator D4003). Libraries were
size-confirmed on an Agilent 2100 Bioanalyzer and subjected to deep
sequencing with single-end 100 bp reads on an Illumina Hi-Seq SR flow cell
platform.
Quantitative PCR of DNA from immunoprecipitated chromatin
(ChIP-PCR)
ChIP samples were analyzed using real-time quantitative PCR in 15 μl
reactions containing 7.5 μl SYBR Green master mix, 2.25 pmol of primers,
and 2 μl of IP, IgG-IP (mock), or input template DNA. The real time PCR
program was run as follows: pre-incubation, ramp at 4.4 °C s−1–95 °C, hold
10min; amplification, 45 cycles (ramp at 4.4 °C s−1–95 °C, hold 10 s, ramp at
2.2 °C s−1–60 °C, hold 30 s, single acquisition); cooling, ramp at 2.2 °C
s−1–40 °C, hold 30 s. To account for sampling 20% of the chromatin prep,
input crossing point (Cp) values were adjusted by subtracting log2(20). % IP
DNA was calculated as 100 × 2^[Cp input - Cp IP]. %Mock-IP DNA was
calculated as 100 × 2^[Cp input - Cp mock] and subtracted from % IP DNA to
determine % IP DNA enrichment relative to mock-IP.
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